


SUBSTITUTE SHEET (RULE 26)









FIG. 3










FIG. 5

WO 01/22093

PCT/US00/24745








FIG. 6







SUBSTITUTE SHEET (RULE 26)




FIG. 9

FIG. 10




FIG. 11








FIG. 12








FIG. 13




FIG. 14





FIG. 15






FIG. 16





FIG. 17










FIG. 18






PCT/US00/24745










FIG. 21

Treatment Group: Placebo PTH20 PTH40 GHAJ - All Randomly Assigned Patients 15 Median Percent Change ≠ SE Procollagen Peptide I -09 20 -10--10-Percent Change

Months since Randomization

Treatment Group Placebo PTH20 PTH40 18 Median Percent Change ± SE GHAJ - All Randomly Assigned Patients Bone Specific Alkaline Phosphatase 15 80 40 9 20 -20 0 Percent Change

Months since Randomization

FIG.




FIG. 24

N - Telopeptide/Creatinine Ratio

WO 01/22093

SUBSTITUTE SHEET (RULE 26)

PCT/US00/24745







FIG. 26











Predicted Change in Spine BMD (g/cm²)

PCT/US00/24745


28/34







SUBSTITUTE SHEET (RULE 26)

29/34






Predicted %Change in Spine BMD at 12 Months




SUBSTITUTE SHEET (RULE 26)


Predicted %Change in Spine BMD at 12 Months








Сряпве in Spine BMD (g/cm²)











FIG. 33


SUBSTITUTE SHEET (RULE 26)

FIG. 34

BSAP at 3 Months (pM)







Change in Spine BMD (g/cm 2)